EOM Pipeline

EOM’s pipeline is built on proprietary innovations designed to rescue, repair, and restore health. These innovations include the development of EOM613, the ­first-and-only investigational dual-acting, broad-spectrum immunomodulator, which has the potential to treat the most severe effects of COVID-19, and its advanced formulation of EOM147, being studied to treat serious retinal diseases without the need for intraocular injection.

EOM613

An investigational, dual-acting, broad-spectrum immunomodulator with pro-inflammatory and anti-inflammatory effects that has already demonstrated clinical improvements in various disease states, and immune-related biomarkers and general tolerability across five Phase 2 clinical trials in patients with cachexia associated with AIDS and cancer, and with patients with rheumatoid arthritis.

EOM147

A first-in-class small molecule anti-angiogenic drug with a novel intracellular mechanism of action for the treatment of proliferative diabetic retinopathy, branch and central retinal vein occlusions, and wet age-related macular degeneration (AMD). The novel formulation represents a potential breakthrough because it does not require intraocular injection into the eye and, if approved, would be the first topically administered eye drop to treat retinal diseases.